131 related articles for article (PubMed ID: 3034033)
21. Effects of the new angiotensin-converting enzyme inhibitor, ramipril, in patients with essential hypertension.
Stumpe KO; Overlack A; Kolloch R; Schatz J; Witte PU; Pahnke K
Klin Wochenschr; 1986 Jun; 64(12):558-62. PubMed ID: 3016405
[TBL] [Abstract][Full Text] [Related]
22. Effect of ramipril on 24-hour variability of blood pressure and heart rate in essential hypertension.
Tochikubo O; Asahina S; Kaneko Y
Am J Cardiol; 1987 Apr; 59(10):83D-85D. PubMed ID: 3034039
[TBL] [Abstract][Full Text] [Related]
23. Interference with the autonomic nervous system by the converting enzyme inhibitor ramipril in conscious spontaneously hypertensive rats.
Moursi M; el-Dakhakhny M; Schölkens BA; Unger T
J Cardiovasc Pharmacol; 1987; 10 Suppl 7():S125-8. PubMed ID: 2485046
[TBL] [Abstract][Full Text] [Related]
24. Efficacy, tolerance and hormonal effects of a new oral angiotensin converting enzyme inhibitor, ramipril (HOE 498), in mild to moderate primary hypertension.
Karlberg BE; Lindström T; Rosenqvist U; Ohman KP
Am J Cardiol; 1987 Apr; 59(10):104D-109D. PubMed ID: 3034016
[TBL] [Abstract][Full Text] [Related]
25. Effects of the new oral angiotensin converting enzyme inhibitor 2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl]-(1S,3S,5S)-2- azabicyclo[3.3.0]octane-3-carboxylic acid (Hoe 498) in essential hypertension.
Felder K; Witte PU
Arzneimittelforschung; 1984; 34(10B):1452-4. PubMed ID: 6097273
[TBL] [Abstract][Full Text] [Related]
26. Metabolic effects of ramipril treatment in hypertensive subjects with non-insulin-dependent diabetes mellitus.
Janka HU; Nuber A; Mehnert H
Arzneimittelforschung; 1990 Apr; 40(4):432-5. PubMed ID: 2141472
[TBL] [Abstract][Full Text] [Related]
27. Converting enzyme inhibitors and brain angiotensin.
Phillips MI; Kimura B
J Cardiovasc Pharmacol; 1986; 8 Suppl 10():S82-90. PubMed ID: 2438497
[TBL] [Abstract][Full Text] [Related]
28. Humoral and blood pressure effects of the angiotensin converting enzyme inhibitor ramipril in essential hypertension.
Lenz T; Distler A; Haller H; Meyer-Sabellek W; Wilp C; Tansey MJ; Eckert HG; Metzger H; Irmisch R; Philipp T
Arzneimittelforschung; 1986 Nov; 36(11):1693-6. PubMed ID: 3028438
[TBL] [Abstract][Full Text] [Related]
29. Preliminary experiences with HOE 498, a novel long-acting converting enzyme inhibitor, in hypertensive patients.
de Leeuw PW; Lugtenburg PL; van Houten H; Looman JH; Birkenhäger WH
J Cardiovasc Pharmacol; 1985; 7(6):1161-5. PubMed ID: 2418304
[TBL] [Abstract][Full Text] [Related]
30. First dose response and 24-hour antihypertensive efficacy of the new once-daily angiotensin converting enzyme inhibitor, ramipril.
Heber ME; Brigden GS; Caruana MP; Lahiri A; Raftery EB
Am J Cardiol; 1988 Aug; 62(4):239-45. PubMed ID: 2969671
[TBL] [Abstract][Full Text] [Related]
31. 2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl]-(1S,3S,5S)-2- azabicyclo[3.3.0]octane-3-carboxylic acid (Hoe 498): antihypertensive action and persistent inhibition of tissue converting enzyme activity in spontaneously hypertensive rats.
Unger T; Fleck T; Ganten D; Lang RE; Rettig F
Arzneimittelforschung; 1984; 34(10B):1426-30. PubMed ID: 6097269
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetic and pharmacodynamic properties of ramipril in patients with congestive heart failure (NYHA III-IV).
Gerckens U; Grube E; Mengden T; Sigel H; Wagner WL; Lahn T; Irmisch R; Metzger H
J Cardiovasc Pharmacol; 1989; 13 Suppl 3():S49-51. PubMed ID: 2474102
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetics and pharmacodynamics of ramipril in renal failure.
Aurell M; Delin K; Herlitz H; Ljungman S; Witte PU; Irmisch R
Am J Cardiol; 1987 Apr; 59(10):65D-69D. PubMed ID: 3034036
[TBL] [Abstract][Full Text] [Related]
34. Pharmacological properties of the new orally active angiotensin converting enzyme inhibitor 2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl] -(1S,3S,5S)-2-azabicyclo[3.3.0]octane-3-carboxylic acid (Hoe 498).
Becker RH; Schölkens BA; Metzger M; Schulze KJ
Arzneimittelforschung; 1984; 34(10B):1411-6. PubMed ID: 6097267
[TBL] [Abstract][Full Text] [Related]
35. Physical performance during sustained converting enzyme inhibition with Hoe 498 in conscious dogs.
Becker RH; Fieber P; Schulze KJ
Arch Int Pharmacodyn Ther; 1985 Dec; 278(2):303-13. PubMed ID: 3006617
[TBL] [Abstract][Full Text] [Related]
36. Ramipril inhibition of rabbit (Oryctolagus cuniculus) small intestinal brush border membrane angiotensin converting enzyme.
Stevens BR; Phillips MI; Fernandez A
Comp Biochem Physiol C Comp Pharmacol Toxicol; 1988; 91(2):493-7. PubMed ID: 2905962
[TBL] [Abstract][Full Text] [Related]
37. Pharmacodynamic, pharmacokinetic and humoral effects of oral zabicipril, an angiotensin converting enzyme inhibitor in normotensive man.
MacDonald NJ; Hughes DM; Lees KR; Reid JL
Br J Clin Pharmacol; 1990 Jul; 30(1):107-13. PubMed ID: 2202384
[TBL] [Abstract][Full Text] [Related]
38. Influence of ramipril on release of norepinephrine during sympathetic nerve stimulation in isolated rabbit hearts.
Xiang JZ; Schölkens BA
Zhongguo Yao Li Xue Bao; 1988 Jul; 9(4):320-2. PubMed ID: 2973724
[No Abstract] [Full Text] [Related]
39. Global and regional hemodynamic effects of ramipril in congestive heart failure.
Crozier IG; Ikram H; Nicholls MG; Jans S
J Cardiovasc Pharmacol; 1989 Nov; 14(5):688-93. PubMed ID: 2481181
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of converting enzyme in brain tissue and cerebrospinal fluid of rats following chronic oral treatment with the converting enzyme inhibitors ramipril and Hoe 288.
Gohlke P; Schölkens B; Henning R; Urbach H; Unger T
J Cardiovasc Pharmacol; 1989; 14 Suppl 4():S32-6. PubMed ID: 2483426
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
